The Rising Use of Off-Label Testosterone Therapy for Menopause
Despite growing popularity, scientific evidence remains limited regarding testosterone's efficacy for menopausal symptom relief.
1Surge in Off-Label Prescriptions
In 2025, U.S. doctors issued over 90,000 off-label testosterone prescriptions to women, primarily aged 45 to 64. This represents a 58.7% increase compared to 2024 data. Because the FDA has not approved testosterone for menopause or perimenopause, these treatments remain outside standard regulatory guidelines, raising significant questions regarding clinical safety and standardized dosing protocols.
2Misconceptions About Hormone Decline
Contrary to popular belief, menopause is not caused by a sharp decline in testosterone levels. While estrogen and progesterone fluctuate and drop during perimenopause, testosterone levels decrease gradually between ages 20 and 60. Experts like Susan Davis note that attributing fatigue or brain fog to androgen deficiency is scientifically inaccurate and unsupported by current research.
3Limited Evidence for General Symptoms
Placebo-controlled trials have consistently failed to demonstrate that testosterone alleviates brain fog, mood swings, or bone density issues. During a September 17 public workshop, the FDA concluded that insufficient evidence exists to support testosterone as a standard menopause treatment. Many patients report improvements, yet these outcomes often mirror the 30% to 40% placebo response rate.
4Focus on Sexual Desire Disorders
Research suggests potential, albeit modest, benefits for hypoactive sexual desire disorder (HSDD) in postmenopausal women. A review of 36 randomized trials involving 8,480 participants showed an average increase of only 0.85 satisfying sexual events per month. Experts emphasize that this effect is not substantial, and testosterone remains unapproved by the FDA for treating HSDD in menopause.
5Dosing Risks and Masculinization
Most global testosterone preparations are formulated for men, leading to dangerous dosing variations when prescribed to women. Excessive intake can trigger unwanted masculinizing effects, including voice deepening, hair thinning, and clitoral enlargement. Because safety profiles for these high-dose regimens are not established, clinicians struggle to adapt male-oriented medications for female metabolic and hormonal profiles.
6The Role of Placebo Effects
Clinical trials frequently encounter high placebo response rates, complicating the evaluation of testosterone efficacy. Approximately one in three participants in various studies reports symptom relief despite receiving no active hormone. This phenomenon makes it difficult to isolate the true physiological impact of the treatment, necessitating larger, more rigorous studies to distinguish actual benefits from psychological expectations.
7Future Research and ESTEEM Trial
The U.K.-based ESTEEM trial is currently investigating the use of testosterone cream for menopausal quality of life. This gold-standard study tracks sleep, memory, anxiety, and physical well-being, with results expected by 2028. Until these findings emerge, the medical community lacks definitive data to confirm if testosterone provides reliable relief for symptoms beyond HSDD.
8Holistic Approach to Menopause
Effective menopause care requires more than pharmacological interventions; it necessitates evaluating lifestyle factors like diet and exercise. Experts warn against treatments promising miraculous results, urging patients to remain cautious of anecdotal claims. Addressing societal pressures regarding aging and physical appearance is equally vital for providing comprehensive support to women navigating this complex life transition.